Quantcast

Lumenis® Introduces SlimLine SIS GI™ Laser Fiber and VersaPulse® P20 Holmium Laser at Digestive Disease Week, Chicago May 7-10, 2011

May 7, 2011

Lumenis Inc. is introducing two new products to the Gastroenterology market, the SlimLine SIS GI Fiber and the VersaPulse P20 Holmium Laser. As part of a relationship with Boston Scientific’s Endoscopy Division, the Company will present these new products in the Boston Scientific booth (#2121) at Digestive Disease Week (DDW), in Chicago May 7-10. The SlimLine SIS GI laser fiber and the P20 Holmium Laser will also be included in the Boston Scientific Hands on Skills Labs in the exhibit hall.

Santa Clara, CA (PRWEB) May 06, 2011

Lumenis Inc. is introducing two new products to the Gastroenterology market, the SlimLine SIS GI Fiber and the VersaPulse P20 Holmium Laser. As part of a relationship with Boston Scientific’s Endoscopy Division, the Company will present these new products in the Boston Scientific booth (#2121) at Digestive Disease Week (DDW), in Chicago May 7-10. The SlimLine SIS GI laser fiber and the P20 Holmium Laser will also be included in the Boston Scientific Hands on Skills Labs in the exhibit hall.

“The SlimLine SIS GI has significantly changed the management of large and difficult stones in our endoscopy suite,” said Dr. Sandeep Patel, Assistant Professor Digestive Disease Center, University of Texas at San Antonio, and co-author of a multi-center study on the use of SlimLine GI and VersaPulse through Boston Scientific’s SpyGlass® Direct Visualization System. “The use of laser energy to break stones has advantages that not only increase our efficiency but allow us to offer patients a less-invasive solution to treating their stones.” Lumenis holmium laser technology for biliary stone management through the SpyGlass System will be presented during SpyGlass Round Table Discussions (Sunday and Monday 11:00 AM ““ 1:00 PM) at the conference by Dr. Sandeep Patel, University of Texas Health Science Center, San Antonio, TX, and Dr. Isaac Raijman, Digestive Associates of Houston, TX.

The presence of stones in the gallbladder affects approximately 10 percent of the adult population in the United States, and stones that have formed or migrated to the common bile duct affect 10-20 percent of patients with gallstone disease. Of the approximately 240K procedures annually to manage bile duct stones, 10-15 percent are large and difficult to manage with conventional methods and may be effectively treated with cholangioscopy and laser therapy.

The SlimLine SIS GI is compatible with Boston Scientific’s SpyGlass System. Access and visualization of the bile duct is obtained through the SpyGlass System and the laser energy is delivered through the cholangioscope via the SlimLine SIS GI laser fiber. Cholangioscope technology such as the SpyGlass System now makes holmium laser lithotripsy a viable option for the GI suite.

The patented design of the SlimLine SIS GI is a modification of Lumenis’ fiber for Gastroenterology and is the only fiber specifically designed for use during cholangioscopy. The special tip of the SlimLine SIS GI prevents it from catching the inside of the cholangioscope working channel, allowing the fiber to be advanced while the scope is in position within the bile duct. Because it slides easily through tight turns in the cholangioscope, physicians no longer have to remove the scope and preload the fiber and thus do not lose position of the scope in the bile duct.

The VersaPulse P20 is Lumenis’ newest laser in the VersaPulse series. The P20 is a compact and portable holmium laser that delivers a full 20 watts of power and has a highly visible green aiming beam. The VersaPulse P20 is simple to use, can be plugged into a standard 110V electrical outlet and is the most cost-effective 20W laser solution available.

“The direct visualization capability of the SpyGlass System in combination with the VersaPulse P20 Holmium Laser and SlimLine SIS GI Fiber provides a unique integrated diagnostic and treatment solution to the customer, in a one-step approach, therefore reducing the overall cost of patient care. The convergence of diagnostic and therapeutic applications is a strategic imperative to reducing the overall cost burden. Our goal is to expand from stone management into other therapeutic indications,” stated Caroline Coyle, Sr. VP and General Manager Lumenis Surgical.

About Lumenis

Lumenis, the world’s largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, ophthalmic and aesthetic applications, with more than 800 employees worldwide. Lumenis has 270 registered patents, over 260 FDA clearances, an installed base of over 30,000 systems and a presence in over 100 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning “Light of Life” highlighting the light, which is the basis of our technologies, used to enhance life. For more information about Lumenis and its products, please visit: http://www.lumenis.com.

For further information contact:

Michelle Maydan

Director of Corporate Communications

1-866-569-0597

+972-4-959-9004

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/5/prweb8395802.htm


Source: prweb



comments powered by Disqus